Literature DB >> 12859594

Expression of HLA class I/II antigens and T cell immune response in human neuroendocrine tumors of the pancreas.

E Ryschich1, F Autschbach, S Eisold, E Klar, M W Buchler, J Schmidt.   

Abstract

Peptide presentation by HLA class I and II antigens regulates specific antigen recognition by T cells. The present study aimed to investigate T cell infiltration and its relation to HLA antigen expression in pancreatic neuroendocrine tumors. Fresh tissue samples were collected from five insulinomas and six other neuroendocrine tumors (one gastrinoma, one glucagonoma, two carcinoid, and two neuroendocrine carcinomas). Normal pancreatic and splenic tissue samples were used as controls. Investigation of infiltrating lymphocyte populations, as well as staining of HLA class I and II antigens, were performed by standard immunohistochemistry. The majority of investigated tumors demonstrated an intratumoral infiltration by CD3+, CD4+ and CD8+ T cells that was significantly higher than in normal pancreatic islets. Only a minority of tumor-infiltrating T cells showed the CD45RO+ phenotype. The expression of HLA class I antigen was altered in 10 of 11 tumors. A loss of beta-2microglobulin represented the most frequent type of alteration to HLA class I expression, although the total loss of HLA class I was found in only one case of neuroendocrine carcinoma. HLA class II molecules were expressed by endothelial and lymphoid cells and not by tumor cells. In conclusion most neuroendocrine pancreatic tumors induce a T cell mediated immune response resulting in an intratumoral infiltration with CD3+, CD4+ and CD8+ T cells. Loss of beta-2microglobulin is a frequent alteration in these tumors, which may influence the normal function of the HLA class I antigen complex. In contrast to malignant tumors of the exocrine pancreas, expression of HLA class II was absent in neuendocrine pancreatic tumor cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12859594     DOI: 10.1034/j.1399-0039.2003.00075.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  9 in total

1.  T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

Authors:  Steven C Katz; Charan Donkor; Kristen Glasgow; Venu G Pillarisetty; Mithat Gönen; N Joseph Espat; David S Klimstra; Michael I D'Angelica; Peter J Allen; William Jarnagin; Ronald P Dematteo; Murray F Brennan; Laura H Tang
Journal:  HPB (Oxford)       Date:  2010-12       Impact factor: 3.647

2.  Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs).

Authors:  Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

3.  Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group.

Authors:  Paula Marincola Smith; Jordan Baechle; Carmen C Solórzano; Marcus Tan; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza Beal; George Poultsides; John G D Cannon; Flavio G Rocha; Angelena Crown; Clifford Cho; Megan Beems; Emily R Winslow; Victoria R Rendell; Bradley A Krasnick; Ryan C Fields; Shishir K Maithel; Christina E Bailey; Kamran Idrees
Journal:  HPB (Oxford)       Date:  2019-12-02       Impact factor: 3.647

4.  Parathyroid chief cell adenoma associated with massive chronic parathyroiditis in a woman with hyperparathyroidism.

Authors:  Kalman Kovacs; Cecil David Bell; Jonathan Juco; Fabio Rotondo; Jennifer Anderson
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

5.  Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature.

Authors:  Aman Chauhan; Millicent Horn; Gray Magee; Kurt Hodges; Mark Evers; Susanne Arnold; Lowell Anthony
Journal:  Oncotarget       Date:  2017-12-28

6.  Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.

Authors:  Massimo Milione; Rosalba Miceli; Francesco Barretta; Alessio Pellegrinelli; Paola Spaggiari; Giovanna Tagliabue; Giovanni Centonze; Cinzia Paolino; Alessandro Mangogna; Ketevani Kankava; Sara Pusceddu; Luca Giacomelli; Ambra Corti; Christian Cotsoglou; Vincenzo Mazzaferro; Gabriella Sozzi; Filippo de Braud; Giancarlo Pruneri; Andrea Anichini
Journal:  J Pathol Clin Res       Date:  2019-07-09

7.  HLA Class I Allele Frequencies in Southern Iranian Women with Breast Cancer.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Iran J Basic Med Sci       Date:  2013-02       Impact factor: 2.699

8.  Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.

Authors:  Tal Grenader; Marianne E Pavel; Philippe B Ruszniewski; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Xuan-Mai Truong Thanh; Martyn E Caplin
Journal:  Anticancer Drugs       Date:  2020-03       Impact factor: 2.389

Review 9.  T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Authors:  Qi Zhou; Xufeng Tao; Shilin Xia; Fangyue Guo; Chen Pan; Hong Xiang; Dong Shang
Journal:  Front Oncol       Date:  2020-03-24       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.